Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases

S. J. Aitken, J. S. Thomas, S. P. Langdon, D. J. Harrison, D. Faratian

Research output: Contribution to journalArticlepeer-review

133 Citations (Scopus)


Background: Assessment of receptors [estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)] is routinely carried out on primary tumour in order to select appropriate adjuvant therapy; the same analysis is not carried out on nodal metastases. Since de novo resistance to therapy is common, we quantified differences in receptor expression between primary and nodal disease in order to assess whether this might contribute to therapeutic resistance.

Patients and methods: A total of 385 patients with invasive primary breast carcinomas and paired lymph nodes (n = 211) were assessed for ER, PR and HER2 expression using quantitative immunofluorescence. Cut-points were defined by comparison with tumours scored by immunohistochemistry (IHC) and FISH. Differences in expression for each of the markers and molecular phenotype were analysed.

Results: Quantitative receptor expression shows a wide dynamic range compared with IHC. Overall, 46.9% cases had disparate breast/node receptor status of at least one receptor. Many of the differences in expression between primary tumour and node are large magnitude (greater than fivefold) changes. Triple-negative phenotype changes in 23.1% of cases.

Conclusions: A significant number of patients show discordant quantitative expression of molecular markers between primary and nodal disease. Appropriately measured, lymph node receptor status could be a more accurate measurement for guiding adjuvant therapy, which requires testing in a clinical trial.

Original languageEnglish
Pages (from-to)1254-1261
Number of pages8
JournalAnnals of Oncology
Issue number6
Publication statusPublished - Jun 2010


Dive into the research topics of 'Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases'. Together they form a unique fingerprint.

Cite this